Supernus Pharmaceuticals (SUPN) Q3 2026 Earnings Call: Revenue Growth, Higher Guidance and Indivior Merger
Source Tradingkey
Key Takeaways
- Supernus Pharmaceuticals reported record Q3 2026 total revenue of $226.8 million, up 18% year over year, driven primarily by Qelbree, Gocovri, Zurzuvae and Onapco.
- GAAP operating earnings reached $21.2 million, compared with a $60.2 million operating loss in Q3 2025. Adjusted operating earnings increased to $55.2 million from $41.9 million.
- Combined revenue from the four growth products rose 43% year over year. Qelbree generated $91 million, Gocovri reached a record $43 million and Zurzuvae collaboration revenue totaled $41.7 million.
- Supernus raised its standalone 2026 revenue guidance to $875 million-$900 million and adjusted operating earnings guidance to $160 million-$180 million.
- Shareholders approved the Indivior Pharmaceuticals merger on October 15, and management expected the transaction to close on November 2. The company remains confident in achieving $125 million in expected annual cost synergies.
Core Financial Data
| Metric | Q3 2026 | Comparison |
|---|---|---|
| Total revenue | $226.8 million | Up 18% year over year |
| Net product sales | $178.6 million | — |
| Zurzuvae collaboration revenue | $41.7 million | Approximately 50% of sales reported by Biogen |
| Royalties, licensing and other revenue | $6.5 million | — |
| Combined R&D and SG&A expenses | $153.8 million | $209.0 million in Q3 2025 |
| GAAP operating earnings | $21.2 million | Loss of $60.2 million in Q3 2025 |
| GAAP net earnings | $20.9 million | Loss of $45.1 million in Q3 2025 |
| Diluted EPS | $0.35 | Loss of $0.80 in Q3 2025 |
| Adjusted operating earnings | $55.2 million | $41.9 million in Q3 2025 |
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Anthropic files for a $2 trillion IPO — the $80.7 billion loss is the decoy, the $450 billion compute bill is the riskAnthropic publicly filed its S-1 on October 26, revealing $16.29 billion of first-half revenue (+1,304% year over year) and a $80.7 billion net loss — of which $72.4 billion is a non-cash convertible-note charge. The real number is the $450 billion of signed, mostly non-cancelable compute commitments. Here is what the filing says, why NVDA, ARM and MU are the tradeable read-through, and the conditions that decide whether the AI trade passes its first public valuation test.
Anthropic publicly filed its S-1 on October 26, revealing $16.29 billion of first-half revenue (+1,304% year over year) and a $80.7 billion net loss — of which $72.4 billion is a non-cash convertible-note charge. The real number is the $450 billion of signed, mostly non-cancelable compute commitments. Here is what the filing says, why NVDA, ARM and MU are the tradeable read-through, and the conditions that decide whether the AI trade passes its first public valuation test.
Brent's $115 front month sits $4.6 above January — the $14 spread to WTI is the supply-risk premiumDecember Brent trades at $115.29 while January is $110.71, a $4.58 backwardation. The December Brent-WTI spread is $14.2, versus a $3-5 normal. That gap, not the headline, is where the Middle East supply risk is priced. Here is what the curve says, why the December contract's expiry on October 30 will mechanically cut the headline by $4.6, and the 108.81 neckline that decides the next move.
December Brent trades at $115.29 while January is $110.71, a $4.58 backwardation. The December Brent-WTI spread is $14.2, versus a $3-5 normal. That gap, not the headline, is where the Middle East supply risk is priced. Here is what the curve says, why the December contract's expiry on October 30 will mechanically cut the headline by $4.6, and the 108.81 neckline that decides the next move.
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 29, 2026. Read on for the details.
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 30, 2026. Read on for the details.
US Q3 GDP rose 3.4%, above the 3.1% estimate, while September headline PCE hit 3.6% and core held at 3.1%. December hike odds are near 90%; inventories, AI capex and energy explain why.
